nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
|
Goji, Takahiro |
|
2015 |
76 |
3 |
p. 615-620 |
artikel |
2 |
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer
|
Fan, Yun |
|
2015 |
76 |
3 |
p. 517-523 |
artikel |
3 |
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
|
Nishina, Tomohiro |
|
2015 |
76 |
3 |
p. 547-553 |
artikel |
4 |
A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors
|
Murakami, Haruyasu |
|
2015 |
76 |
3 |
p. 631-639 |
artikel |
5 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors
|
Henary, H. |
|
2015 |
76 |
3 |
p. 597-603 |
artikel |
6 |
AT-101 inhibits hedgehog pathway activity and cancer growth
|
Wang, Juan |
|
2015 |
76 |
3 |
p. 461-469 |
artikel |
7 |
Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612)
|
Parise, Robert A. |
|
2015 |
76 |
3 |
p. 537-546 |
artikel |
8 |
Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis
|
Li, Jie |
|
2015 |
76 |
3 |
p. 651-655 |
artikel |
9 |
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors
|
Patnaik, Amita |
|
2015 |
76 |
3 |
p. 587-595 |
artikel |
10 |
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
|
Fogelman, David |
|
2015 |
76 |
3 |
p. 489-498 |
artikel |
11 |
Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells
|
Yang, Dan |
|
2015 |
76 |
3 |
p. 575-586 |
artikel |
12 |
Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1
|
Ying, Liu |
|
2015 |
76 |
3 |
p. 641-650 |
artikel |
13 |
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients
|
Gupta, Neeraj |
|
2015 |
76 |
3 |
p. 507-516 |
artikel |
14 |
In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs
|
Yin, Jia-Xue |
|
2015 |
76 |
3 |
p. 525-536 |
artikel |
15 |
Lower antioxidative capacity of multidrug-resistant cancer cells confers collateral sensitivity to protoflavone derivatives
|
Stanković, Tijana |
|
2015 |
76 |
3 |
p. 555-565 |
artikel |
16 |
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients
|
Claret, Laurent |
|
2015 |
76 |
3 |
p. 567-573 |
artikel |
17 |
NECTIN-4 increased the 5-FU resistance in colon cancer cells by inducing the PI3K–AKT cascade
|
Das, Dipon |
|
2015 |
76 |
3 |
p. 471-479 |
artikel |
18 |
Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer
|
Suleiman, Yaman |
|
2015 |
76 |
3 |
p. 481-487 |
artikel |
19 |
Predictive value of STMN1 gene promoter polymorphism (−2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine
|
Mlak, Radosław |
|
2015 |
76 |
3 |
p. 621-629 |
artikel |
20 |
Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats
|
Gonzalez, Yanira |
|
2015 |
76 |
3 |
p. 447-459 |
artikel |
21 |
RETRACTED ARTICLE: ABCB1 (1199G>A) polymorphism regulates the efficacy of docetaxel and imatinib mesylate in HEK293 recombinant cell lines
|
Peng, Rui |
|
2015 |
76 |
3 |
p. 657 |
artikel |
22 |
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate
|
Petrioli, Roberto |
|
2015 |
76 |
3 |
p. 439-445 |
artikel |
23 |
Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease
|
Enomoto, Yasunori |
|
2015 |
76 |
3 |
p. 499-505 |
artikel |
24 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies
|
Iwasa, Satoru |
|
2015 |
76 |
3 |
p. 605-614 |
artikel |